RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire-FirstCall/ -- Integrated
systems biology company Icoria, Inc. (Nasdaq: ICOR), announced today that it
will report its fourth quarter and year-end results for the period ending
December 31, 2004, after the close of trading on March 1.
The company's management team will conduct a conference call and webcast
to discuss the results on Wednesday, March 2, at 8:30 a.m. ET. Interested
participants should call 1-800-500-0311 or, for those calling internationally,
01-719-457-2698. The conference call ID number is 9923340. Icoria encourages
participants to dial in 10 minutes before the call commences.
The webcast can be accessed from Icoria's web site
at http://www.icoria.com by clicking on the Investor Relations link. For
those unable to participate, replays of the call may be heard online
at http://www.icoria.com . Supplemental information will also be available
online.
About Icoria
Icoria, Inc. is a biotech company dedicated to deciphering the complexity
of biological processes through the application of systems biology to identify
biomarkers for drug discovery and development, diagnostics and to develop
novel agrichemicals. Icoria has major contracts with the National Institute
of Environmental Health Sciences, the Monsanto Company and Pioneer Hi-Bred
International (a subsidiary of DuPont). Icoria also has a major grant from
the National Institute of Standards & Technology's Advanced Technology
Program. For more information, visit http://www.icoria.com .
This press release contains forward-looking statements. Such forward-
looking statements are based on management's current expectations and are
subject to a number of risks, factors and uncertainties that may cause actual
results, events and performance to differ materially from those referred to in
the forward-looking statements. These risks, factors and uncertainties
include, but are not limited to, Icoria's early stage of development, history
of net losses, technological and product development uncertainties, reliance
on research collaborations, uncertainty of additional funding and ability to
protect its patents and proprietary rights. Certain of these and other risks
are identified in Icoria's annual report on Form 10-K for the year ended
December 31, 2003 and in its quarterly report on Form 10-Q for the quarter
ended September 30, 2004, each filed with the Securities and Exchange
Commission. The Company does not intend to update any of the forward-looking
statements after the date of this release to conform these statements to
actual results or to changes in our expectations, except as may be required by
law.
SOURCE Icoria, Inc.
 back to top
Related links:
http://www.icoria.com
CONTACT:
Media-Public Relations of Icoria, Inc.,
+1-919-425-2999; or Brian Ritchie, or Mark Vincent of EURO RSCG
Life NRP, +1-212-845-4200
|
